Case Study: Leading Pharmaceutical Company achieves 43% faster enrollment (900 patients in 30 weeks) with IQVIA

Unique predictive enrollment model reduced projected enrollment period from 52 to 30 weeks

Leading Pharmaceutical Company engaged IQVIA (through IQVIA Biotech) to provide patient recruitment services for a Phase III external genital warts study. The sponsor’s challenge was to enroll 900 young adults (ages 18–30)—a transient, hard-to-reach population—and ensure an even male/female distribution within a tight timeline.

IQVIA deployed its predictive enrollment model and tailored patient recruitment program—including demographic-specific messaging, spot-market advertising, and daily tracking to optimize site-level recruitment in real time. The campaign fully enrolled 900 randomized patients in 30 weeks versus the projected 52 weeks (a 43% reduction, 22 weeks ahead), achieved an approximately even gender split, and lowered per-response advertising costs so media investment stayed below projection.